PARTNER: randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Authors
Abraham, JEPinilla, K
Vallier, AL
Grybowicz, L
Qian, W
Thomas, S
Weiss, M
Harvey, C
Kateb, A
Machin, A
Demiris, N
Wulff, J
McAdam, K
Hughes-Davies, L
Roberts, A
Roylance, R
Copson, E
Armstrong, Anne C
Levitt, N
Provenzano, E
Tischkowitz, M
McMurtry, E
Earl, H
Affiliation
University of Cambridge, CambridgeIssue Date
2020